People: Resverlogix Corp (RVX.TO)
13 Sep 2019
Dr. Michael T. Sweeney, M.D., is Senior Vice President - Clinical Development of the Company. Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications. This will include the company's Phase 2/3 trial of RVX-208 in patients with high-risk CVD with low HDL and diabetes mellitus. Dr. Sweeney has an impressive career history, including 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of marketing of the Viagra(R) Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was a strategic pharmaceutical consultant for Impax Pharmaceuticals, Inc., a specialty pharmaceutical company with drug delivery and formulation technology, where he prepared a European marketing authorization application (MAA) for a product to treat neurologic disease. Prior to Impax, Dr. Sweeney was Chief Medical Officer and vice president of research and development at Depomed, Inc., where he implemented the company's strategic plan for product development activities including opportunity assessment, clinical trials and interactions with the FDA. Prior to Depomed, Dr. Sweeney was vice president of medical affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa(R) for patients with cardiovascular disease and chronic angina. Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He also is a fellow of the Royal College of Physicians of Edinburgh.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|